The Urethral Stricture Treatment Market, estimated at USD 1,868.8 Mn in 2025, is expected to exhibit a CAGR of 6.2% and reach USD 2,847.3 Mn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Rising prevalence of urethral stricture patients, and increasing demand from the hospitals is expected to drive the global urethral stricture treatment market growth over the forecast period. For instance, an article published by National Center for Biotechnology Information (NCBI), stated that Urethral stricture is a relatively common disease in men with an associated prevalence of 229-627 per 100,000 males in U.S. , 0.6% of the population at risk, who are typically older men, the prevalence of the urethral stricture treatment increasing gradually.
Global Urethral Stricture Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.
COVID-19 had a impact on negatively the global urethral stricture treatment market. For instance, in September 2025, a article published in the National Center for Biotechnology Information NCBI, according to which Comparisons of March 11 to June 4, 2025, and the same days in the previous four years revealed that total public attention to reconstructive urology significantly declined, the inquiries including urethroplasty, urethrotomy, hypospadias, cystocele, rectocele, bladder augmentation, vesicourethral reflux, pyeloplasty, vesicovaginal fistula, male sling, and artificial urinary sphincter were significantly was significantly lower in comparison to the same period between 2016 and 2025.
Global Urethral Stricture Treatment Market: Key Developments
Increasing launches of the product by the key market players is expected to drive the global urethral stricture treatment market growth over the forecast period. In January 2025, Laborie, got approval from U.S. Food and Drug Administration (FDA), for Optilume a drug coated balloon (DCB).
Browse 45 Market Data Tables and 37 Figures spread through 195 Pages and in-depth TOC on “Global Urethral Stricture Treatment Market, By Type (Posterior Urethral Stricture and Anterior Urethral Stricture), By Treatment (Urethral Dilation, Direct Vision Internal Urethrotomy (DVIU), Urethroplasty (Anastomotic Urethroplasty and Substitution Urethroplasty), and others), By Disease Indication (Latrogenic, Idiopathic, Infection-induced, Trauma, and others), By End User (Hospitals, Ambulatory Surgical Centers, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/urethral-stricture-treatment-market-2381
Key Takeaways of the Global Urethral Stricture Treatment Market:
- Global urethral stricture treatment market is expected to exhibit a CAGR of 6.2% during the forecast period. In May 2025, according to the data published by the National Center for Biotechnology Information (NCBI), although this is still ongoing, current research appears to focus on improving the success of DVIU using regenerative medicine and tissue-engineered products.
- Among type, the anterior urethral stricture segment is expected to dominant the global urethral stricture treatment market over the forecast period, due to increasing number of males having urethral stricture
- Major players operating in the global urethral stricture treatment market include Becton, Dickinson and Company, Amecath, Zhejiang Chuangxiang, Medical Technology Co., Ltd, Allium Ltd., SURGIMEDIK, Cook Group, Taewoong Medical Co, Ltd., Teleflex Incorporated, B. Braun Melsungen AG, Coloplast A/S, Boston Scientific Corporation, and Pnn Medical A/S, and ,
Contact Us